Fig. 3.
Fig. 3. Survival. / Survival from randomization (P = .77, log rank test). The patients who received alloBMT in first CP were censored at the date of BMT. The number of cases at risk at 12, 24, 36, 48, and 60 months is 246, 217, 181, 111, and 53, respectively, in the IFN-α–plus–LDAC arm, and 225, 178, 151, 100, and 49, respectively, in the IFN-α arm.

Survival.

Survival from randomization (P = .77, log rank test). The patients who received alloBMT in first CP were censored at the date of BMT. The number of cases at risk at 12, 24, 36, 48, and 60 months is 246, 217, 181, 111, and 53, respectively, in the IFN-α–plus–LDAC arm, and 225, 178, 151, 100, and 49, respectively, in the IFN-α arm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal